TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00151892
Drug: SPD476
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day Once Daily (QD)
Study: NCT02826772
Drug: GT0918
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-tumor activity
Study: NCT03077165
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT02707640
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo, oral administration, three times daily for 24 weeks.
Study: NCT02557984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Pill
Study: NCT02517905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration
Study: NCT01678534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03501979
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is approved by the FDA and is available commercially as an oral drug.
Study: NCT03011645
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth, single dose.
Study: NCT02129673
Drug: VS101 Insert Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release of latanoprost into the eye
Study: NCT02129673
Drug: VS101 Insert Dose B
Normalized name: oxytetracycline / polymyxin B Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release of latanoprost into the eye
Study: NCT00927641
Drug: Ketoprofen Patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
Study: NCT01221259
Drug: E2212
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single ascending doses ranging from 10mg to 250mg
Study: NCT01221259
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of matching placebo
Study: NCT01730248
Drug: INC424
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablets administered orally twice daily
Study: NCT01730248
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 50 mg hard gelatin capsules administered orally once daily
Study: NCT00448292
Drug: Placebo for PRX-00023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Study: NCT03033329
Drug: Single intravenous doses of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single doses of placebo to match MRX-4
Study: NCT03033329
Drug: Multiple intravenous doses of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
Study: NCT03033329
Drug: Single dose of intravenous and oral MRX-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
Study: NCT04390152
Drug: Wharton's jelly derived Mesenchymal stem cells.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Wharton's jelly derived Mesenchymal stem cells, two doses
Study: NCT04390152
Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
Study: NCT04250597
Drug: GNX102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation
Study: NCT04250597
Drug: GNX102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expansion Phase
Study: NCT02855944
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
Study: NCT03946163
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
Study: NCT00745914
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04280874
Drug: Dinoprostone 0.5 MG
Normalized name: dinoprostone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg dinoprostone applied intracervically
Study: NCT04280874
Drug: Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg dinoprostone applied intravaginally
Study: NCT01530243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as tolterodine and terazosin dose
Study: NCT02784093
Drug: Gastrograﬁn
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00684177
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Study: NCT01446809
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03148210
Drug: Treatment strategy using evidence-based guidelines for asthma or COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
Study: NCT03265119
Drug: AEVI-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
Study: NCT03265119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
Study: NCT02099201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00975143
Drug: CIP-Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
Study: NCT02685774
Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
Study: NCT02685774
Drug: CKD-395 0.25/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-395 0.25/500mg 2T oral administration
Study: NCT02321865
Drug: NPC-02
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293384
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
Study: NCT02478580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given before surgery
Study: NCT02232256
Drug: CALPXT96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
Study: NCT03079440
Drug: TEMCAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
Study: NCT00140075
Drug: Epirubicin with Cyclophosphamide, followed by a Taxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Study: NCT01231165
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/daily for 12th months
Study: NCT01822613
Drug: LJM716
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Study: NCT01822613
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Study: NCT03724448
Drug: aleozen
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with herbal medicine
Study: NCT03724448
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aleozen treatment
Study: NCT01792518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00861718
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, QD
Study: NCT00861718
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, BID
Study: NCT00861718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral BID
Study: NCT02247869
Drug: dose dense ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14
Study: NCT00333229
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
Study: NCT00333229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01907633
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
Study: NCT00192075
Drug: 5FU/folinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
Study: NCT00649116
Drug: Lopressor® Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT02224872
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV on days -6, -5, 3, 4
Study: NCT02224872
Drug: Mycophenolic acid mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg PO/IV TID beginning on day 5 through day 35
Study: NCT04608266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
Study: NCT03527212
Drug: SJP-0035 0.001%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
Study: NCT03527212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
Study: NCT00003060
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003060
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00722293
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
Study: NCT00452803
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Study: NCT00452803
Drug: Concurrent chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Study: NCT00687453
Drug: NPH twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of morning NPH to bedtime NPH
Study: NCT01742429
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01742429
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic
Study: NCT00393718
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide placebo. Injected s.c. (under the skin) once daily.
Study: NCT03431194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098839
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00393718
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide placebo. Given orally once or twice daily.
Study: NCT01030614
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
Study: NCT00098839
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2/day PO divided BID or TID
Study: NCT00098839
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00098839
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00098839
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02285530
Drug: TPF induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
Study: NCT01938534
Drug: Helicobacter pylori eradication
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00531193
Drug: BIIB014
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
Study: NCT01174030
Drug: CD07805/47 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD07805/47 Gel 0.5% QD
Study: NCT01174030
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel QD
Study: NCT01174030
Drug: CD07805/47 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD07805/47 Gel 0.18% QD
Study: NCT01174030
Drug: CD07805/47 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD07805/47 Gel 0.18% BID
Study: NCT01174030
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel BID
Study: NCT02624102
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
Study: NCT03100825
Drug: QVM149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
Study: NCT06129812
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Study: NCT02560298
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02560298
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01197469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00559962
Drug: AEGR-733
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules each evening for each 4-week period
Study: NCT00559962
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules each evening for each 4-week period
Study: NCT03410979
Drug: GLPG2737 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2737 oral suspension, single ascending doses
Study: NCT03410979
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral suspension.
Study: NCT03410979
Drug: GLPG2737 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
Study: NCT03410979
Drug: GLPG2737 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral suspension, daily for 14 days
Study: NCT02059148
Drug: LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00262990
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00756951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00756951
Drug: SCV-07
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg
Study: NCT00756951
Drug: SCV-07
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg
Study: NCT00000480
Drug: anti-arrhythmia agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231268
Drug: Gladem
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01994993
Drug: ampicillin and metronidazole and gentamicin
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study: NCT01994993
Drug: ampicillin and gentamicin and clindamycin
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study: NCT01994993
Drug: gentamicin and Piperacillin- tazobactam
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study: NCT01994993
Drug: metronidazole, clindamycin, or piperacillin-tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
Study: NCT04680949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
Study: NCT02412059
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04052776
Drug: Buspirone + Levodopa-Carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg + 400mg/100mg
Study: NCT04052776
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active metabolite
Study: NCT00513396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Study: NCT00969072
Drug: GI198745 0.05mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Study: NCT00969072
Drug: GI198745 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Study: NCT00969072
Drug: GI198745 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI198745 (drug) - benign prostatic hyperplasia
Study: NCT01621867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
Study: NCT00003196
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo cytoreductive chemotherapy
Study: NCT02558348
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04538625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT04023682
Drug: Provodine Hand Sanitizer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention with Provodine
Study: NCT02386943
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication is taken.
Study: NCT04143451
Drug: Aldara 5% Topical Cream
Normalized name: Aldara 5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: imiquimod cream
Study: NCT04143451
Drug: Aqueous cream BP
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive aqueous cream
Study: NCT00940303
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 iv infusion, day 1 every 2 weeks
Study: NCT02562313
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog® bolus infusion followed by test meal intake
Study: NCT00544596
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01493271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to RO5093151